Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Clinical Trials
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Goodman, S. N
Right arrow Articles by Sladky, J. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodman, S. N
Right arrow Articles by Sladky, J. T
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre

Steven N Goodman

Departments of Oncology, Pediatrics, Epidemiology and Biostatistics, Johns Hopkins School of Medicine and Public Health

John T Sladky

Department of Pediatric Neurology, Emory University School of Medicine; Emory University School of Medicine, 1440 Clifton Road N.E., Atlanta, GA 30322, USA

Background Guillain-Barré syndrome (GBS) is a rare neurologic disease that occurs at all ages, causing a progressive, ascending paralysis that usually resolves over weeks or months. The disease appears to be identical in children and adults, except that children recover more quickly, with fewer residua. For patients who lose the ability to walk independently, the main treatment options are plasmapheresis or intravenous immune globulin (IVIg), treatments that have shown to have identical effectiveness in adults in two large RCTs involving 388 patients. The effectiveness of the treatments in children has only been studied in small, poorly controlled studies. If one could capture all eligible patients in the United States, only about 100–300 children would be available for a trial annually.

Methods The goal of this case was to demonstrate how Bayesian methods could be used to incorporate prior information on treatment efficacy from adults to design a randomized noninferiority trial of IVIg versus plasmapheresis in children. A Bayesian normal–normal model on the hazard ratio of time to independent walking was implemented.

Results An evidence-based prior was constructed that was equivalent to 72 children showing exact equivalence between the therapies. A design was constructed based on a Bayesian normal–normal model on the hazard ratio, yielding a sample size of 160 children, with a preposterior analysis demonstrating a "Type I" error rate of 5% and a power of 77%.

Conclusions This case study illustrates a rational approach to constructing an evidence-based prior that would allow information from adults to formally augment data from children to minimize unnecessary pediatric experimentation. The frequentist properties of a Bayesian design can be evaluated and reported as they would be for a standard design. Discussion of the appropriate prior for such designs is both a necessary and desirable feature of Bayesian trials.

Clinical Trials, Vol. 2, No. 4, 305-310 (2005)
DOI: 10.1191/1740774505cn102oa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement